Director Christopher Gibson of Recursion Pharmaceuticals NASDAQ:RXRX, sold 40,000 shares of Class A Common Stock on January 5, 2026, at a price of $4.25, totaling $170,000. The transaction occurred as ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. In 2025, more than 1,700 class lawsuits were settled for a total of $79 billion—nearly ...

CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...